Renerve Ltd
RNV
Company Profile
Business description
Renerve Ltd specializes in developing a range of ready-to-use products that are cleaner, safer for repairing or replacing damaged peripheral nerves, resulting in good patient outcomes. Its product candidates include NervAlign Bionic Nerve, NervAlign Nerve Graft, and NervAlign Nerve Cuff [The NervAlign Nerve Guide Matrix, The NervAlign Nerve Conduit, The NervAlign Bionic Replacement Nerve]. The company operates in New Zealand and USA. Maximum of revenue is from USA.
Contact
157 Heidelberg Road
NorthcoteVIC3070
AUST: +61 394823940
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Strong finish to the year for overvalued ASX share
A great fiscal 2025 but investors are ahead of themselves.
stocks
Our three most overvalued ASX shares
These three companies are trading at a significant premium to our fair value.
stocks
What does big US court decision mean for Google’s parent company Alphabet?
Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,070.80 | 49.70 | -0.54% |
| CAC 40 | 7,734.84 | 60.06 | 0.78% |
| DAX 40 | 23,807.13 | 210.15 | 0.89% |
| Dow JONES (US) | 45,514.95 | 114.09 | 0.25% |
| FTSE 100 | 9,221.44 | 13.23 | 0.14% |
| HKSE | 25,830.53 | 196.62 | 0.77% |
| NASDAQ | 21,798.70 | 98.31 | 0.45% |
| Nikkei 225 | 43,656.54 | 12.73 | 0.03% |
| NZX 50 Index | 13,227.90 | 53.24 | -0.40% |
| S&P 500 | 6,495.15 | 13.65 | 0.21% |
| S&P/ASX 200 | 8,792.70 | 48.20 | -0.55% |
| SSE Composite Index | 3,815.61 | 11.24 | -0.29% |